Paraneoplastic Thrombocytosis in Ovarian Cancer
Top Cited Papers
- 16 February 2012
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 366 (7), 610-618
- https://doi.org/10.1056/nejmoa1110352
Abstract
The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that platelets play in abetting cancer growth are unclear. We analyzed clinical data on 619 patients with epithelial ovarian cancer to test associations between platelet counts and disease outcome. Human samples and mouse models of epithelial ovarian cancer were used to explore the underlying mechanisms of paraneoplastic thrombocytosis. The effects of platelets on tumor growth and angiogenesis were ascertained. Thrombocytosis was significantly associated with advanced disease and shortened survival. Plasma levels of thrombopoietin and interleukin-6 were significantly elevated in patients who had thrombocytosis as compared with those who did not. In mouse models, increased hepatic thrombopoietin synthesis in response to tumor-derived interleukin-6 was an underlying mechanism of paraneoplastic thrombocytosis. Tumor-derived interleukin-6 and hepatic thrombopoietin were also linked to thrombocytosis in patients. Silencing thrombopoietin and interleukin-6 abrogated thrombocytosis in tumor-bearing mice. Anti–interleukin-6 antibody treatment significantly reduced platelet counts in tumor-bearing mice and in patients with epithelial ovarian cancer. In addition, neutralizing interleukin-6 significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer. The use of an antiplatelet antibody to halve platelet counts in tumor-bearing mice significantly reduced tumor growth and angiogenesis. These findings support the existence of a paracrine circuit wherein increased production of thrombopoietic cytokines in tumor and host tissue leads to paraneoplastic thrombocytosis, which fuels tumor growth. We speculate that countering paraneoplastic thrombocytosis either directly or indirectly by targeting these cytokines may have therapeutic potential. (Funded by the National Cancer Institute and others.)Keywords
This publication has 25 references indexed in Scilit:
- Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulationPublished by Wiley ,2007
- Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinomaNature Medicine, 2006
- Lineage-Specific Hematopoietic Growth FactorsThe New England Journal of Medicine, 2006
- Stress Hormone–Mediated Invasion of Ovarian Cancer CellsClinical Cancer Research, 2006
- Identification of a Novel Estrogen-Regulated Gene, EIG121, Induced by Hormone Replacement Therapy and Differentially Expressed in Type I and Type II Endometrial CancerClinical Cancer Research, 2005
- Thrombopoietin Production in Wild-Type and Interleukin-6 Knockout Mice with Acute InflammationJournal of Interferon & Cytokine Research, 2005
- Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive DiseaseCancer Research, 2005
- Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosisBlood, 2001
- Megakaryocyte Quantifications in Relation to Thrombokinetics in Primary Thrombocythaemia and Allied DiseasesScandinavian Journal of Haematology, 1975
- Thrombocytosis Associated With Malignant DiseaseArchives of Internal Medicine, 1964